Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 755 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Raised Intraocular Pressure Clear all

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: No Treatment; Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Primary Open Angle Glaucoma
Interventions: VISIOR video goggles; Device
Lead sponsor: Visior Technologies Ltd.; Industry
Eligibility: 30 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Open Angle Glaucoma (OAG), Ocular Hypertension (OHT)
Interventions: iDose TR (travoprost intracameral implant) 75 µg; Combination Product
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Vehicle; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 11
States / cities: Newport Beach, California • Fairfield, Connecticut • Roswell, Georgia + 8 more

Conditions: Open-angle Glaucoma, Diabetic Retinopathy
Interventions: GlaucoHealth, GlaucoSelect, Placebo; Drug
Lead sponsor: The New York Eye & Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Ocular Hypertension
Interventions: Latanoprost eluting contact lens, Topical Latanoprost; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma
Interventions: Perimetric test; Diagnostic Test
Lead sponsor: Envision Health Technologies, Inc.; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Open-angle Glaucoma or Ocular Hypertension
Interventions: DE-117 ophthalmic solution, latanoprost ophthalmic solution, Placebo; Drug · Other
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 7
States / cities: Newport Beach, California • Morrow, Georgia • Kansas City, Missouri + 4 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Xalacom, Xalatan, Timolol; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 64
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Artesia, California + 52 more

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost, Timolol 0.5%, Placebo Ocular Insert, Placebo Eye Drops; Drug · Device
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 10
States / cities: Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 7 more

Conditions: Glaucoma, Glaucoma, Open-Angle
Interventions: AqueSys Microfistula Implant; Device
Lead sponsor: AqueSys, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 14
States / cities: Fayetteville, Arkansas • Los Angeles, California • San Diego, California + 11 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide/Timolol; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Primary Open-angle Glaucoma, Ocular Hypertension
Interventions: OPA-6566, Placebo, Latanoprost; Drug
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: Artesia, California • Glendale, California • Roswell, Georgia + 6 more

Conditions: Retinal Disease, Glaucoma
Interventions: P200TE, Spectral OCT/SLO; Device
Lead sponsor: Optos, PLC; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Glaucoma, Open Angle, Ocular Hypertension
Interventions: Timolol Maleate in Sorbate, Timolol hemihydrate, Timolol maleate gel forming solution; Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 2
States / cities: Bourbonnais, Illinois • Charlotte, North Carolina

Conditions: Glaucoma, Open-Angle, Eye Diseases
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Glaucoma, Open-angle, Ocular Hypertension
Interventions: Travatan; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Open-Angle Glaucoma
Interventions: VISCO360 ab interno canaloplasty surgery, Selective Laser Trabeculoplasty (SLT); Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Fayetteville, Arkansas • Orange, California • Oklahoma City, Oklahoma + 3 more

Conditions: Glaucoma, Open-Angle
Interventions: Video education on proper eye drop instillation technique, Placebo video education on healthy eating tips; Other
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration, Placebo, 0.005% latanoprost; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 14
States / cities: Artesia, California • Los Angeles, California • Torrance, California + 9 more

Conditions: Glaucoma, Intraocular Pressure, Optic Neuropathy
Interventions: Not listed
Lead sponsor: Wills Eye; Other
Eligibility: Not listed
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma
Interventions: OCT; Device
Lead sponsor: Heidelberg Engineering GmbH; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2023
U.S. locations: 8
States / cities: La Jolla, California • Santa Monica, California • Mt. Dora, Florida + 5 more

Conditions: Glaucoma, Ocular Hypertension, Normal Tension Glaucoma
Interventions: This is observational IOP measurement; Device
Lead sponsor: Intuor Technologies, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 198 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: Tucson, Arizona • Memphis, Tennessee

Conditions: Primary Open Angle Glaucoma or Ocular Hypertension
Interventions: AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Placebo; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 40
States / cities: Chandler, Arizona • Phoenix, Arizona • Azusa, California + 29 more

Search by objective public record fields.

Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)

The Effects of Visior on Ocular Hemodynamics

iDose TR Administration in an Office-Based Surgery Setting

Study of AR-13324 in Patients With Elevated Intraocular Pressure

Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy

Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension

Perimetric Testing With Virtual Reality

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

Dose-Ranging Study of the Bimatoprost Ocular Insert

AqueSys Microfistula Implant in Refractory Glaucoma

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes

Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension

The Flashing Light-Induced Pupil Response (FLIPR) Glaucoma Study

A Long-term Safety Study of Once-daily Travatan

Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma

Glaucoma Eye Drop Instillation: Impact of Education

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Comparing Rates of Glaucoma in Professional Wind Versus Non-Wind Instrument Players

Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-1)

EVALUATION of CATS TONOMETER PRISM in LASIK SUBJECTS

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension